Abstract: Promotion of bone repair contributes to the shortening of the treatment period and improvement of the therapeutic effect in large bone defects. The purpose of the present study was to determine the optimal condition for the administration of growth factors to facilitate bone repair and explore the significance of angiogenesis in bone regeneration in vivo. Critical-size calvarial defects were created in the parietal bones of adult ddY mice, and the defects were treated with gelatin sponges impregnated with growth factors BMP-2, FGF-2, and HGF, alone or in combination. The bone regeneration at 1, 2, 3, and 4 weeks was evaluated using micro-computed tomography and histological observation. Critical-size calvarial defects were also created in Flk1-GFP mice to analyze angiogenesis in the early phase of bone repair. The proliferation of Flk1-GFP positive endothelial cells during bone repair was quantitatively evaluated using immunohistochemistry for Ki67. Treatment with a combination of BMP-2 and HGF (BMP-2+HGF) significantly induced more new bone formation within the bone defects compared with the other groups. Compared with BMP-2 alone, bone regeneration was rapidly increased by BMP-2+HGF from 3 weeks of the beginning of the treatment. The number of FLK1-GFP and Ki67 double positive cells in the defect areas of mice administered BMP-2+HGF at 1 week was larger than that in those administered BMP-2 alone. These results indicate that the combination of BMP-2 and HGF was markedly efficient in bone regeneration due to the promotion of angiogenesis in the early phase of bone repair.
Introduction
The repair of bone defects is a major clinical challenge for orthopedic and oral-maxillofacial surgeons. These days, the bone defects caused by injury, infection, tumor resection, and skeletal abnormalities are treated using autologous bone grafts, allografts, or bone prosthetic materials such as titanium, hydroxyapatites, synthetic meshes, or allogeneic demineralized bone. Autologous bone grafting is considered the gold standard because of its high safety due to the use of the patient's own tissues. Autologous grafts also show superior conduction ability and bone inductive potential for living bone cells. However, there are limitations to the quantity of bone that can be collected, and the risk of complications such as pain, deformity, infection, and postoperative absorption exists 1) .
Although quantity is not a limitation in allogeneic bone grafting, it is associated with infection, low quality of bone, and delayed healing 1) . Bone prosthetic materials have low mechanical strength and lack bone inductive potential and symphysis 2) . Therefore, new treatments for bone defects should be developed, which can be used as alternatives to autografting, allografting, and application of bone prosthetic materials.
Recently, one of the predominant goals in the treatment of bone defects has been to enhance bone regeneration using growth factors. Growth factors play an important role in cellular functions such as proliferation and differentiation under physical and pathological conditions, and various growth factors have been shown to promote the sequential bone development cascade 3, 4) .
J.Hard Tissue Biology Vol. 24 (1) : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , 2015 categorized as BMPs in humans. Among these, eight BMPs (BMP-1 to BMP-8a) have an osteochondral function 8) through phosphorylation of specific Smad proteins in mesenchymal stem cells 9, 10) . Thus, BMPs has become an important object in biological and medical research fields associated with bone regeneration and development. Numerous studies demonstrated variable increases in bone regeneration after a single administration of BMP-2 in both large and small animal models with direct and indirect deliveries by viral or non-viral transfection 11) , and the efficacy of BMP-2 on bone regeneration has been presented in clinical trials 12, 13) . Additionally, to further potentiate the bone induction ability of BMP-2, a number of studies have investigated the use of other growth factors such as other BMPs, HGF, and FGFs, which have angiogenic properties, in combination with BMP-2, and demonstrated the synergistic effects either in vivo or in vitro 11, [14] [15] [16] [17] [18] [19] [20] . Angiogenesis plays a vital role during bone repair/ regeneration [21] [22] [23] . However, the efficacy of these growth factors on BMP-mediated osteo-/angiogenesis in vivo remains controversial, particularly in the field of cranial bone regeneration.
Therefore, in this study, we aimed to determine the effective combination of growth factors to facilitate bone regeneration in vivo and clarified the significance of angiogenesis by using a mouse critical-size bone defect model.
Materials and Methods

Calvarial defects and surgical procedure
The mice (ddY, 8 weeks old, male) were obtained from Japan SLC (Shizuoka, Japan) and maintained in plastic cages in a room at an ambient temperature of 23 ± 1 °C with ad libitum access to water and standard laboratory pellet diet. Calvarial defects were created in the parietal bone of the mice using a high-speed dental drill (Portacare 21, Morita, Tokyo, Japan). The mice were anesthetized using 2.5 % isoflurane and 1L/min oxygen. After cleaning of the surgical site with povidone iodine solution, an incision was made just off the sagittal midline to expose the parietal bone. The periosteum on the parietal bone was carefully peeled off with fine forceps. Using a trephine bar (Sophia Tech, Inc. Tokyo, Japan) and saline irrigation, unilateral full-thickness calvarial defects were created in the non-suture-associated right and left parietal bone. Then, gelatin sponges (MedGel, Medgel Inc. Tokyo, Japan) with growth factors were implanted, and the skin and periosteum were restored and sewed. Regarding the size of the bone defects, since 2 mm was reportedly accepted to be the critical size for the mouse calvarial defect 24) , additionally we reconfirmed that a defect 2.4 mm in size implanted with gelatin sponges and normal saline did not demonstrate significant radiographic or histological evidence of spontaneous healing after 12 weeks (data not shown). Thus, we determined that a diameter of 2.4 mm was the critical-size defect for this study. combinations) was dropped onto the freeze-dried sponge, followed by incubation at 37 for 1 h before implantation. The resulting sponge was used as the gelatin incorporated with growth factors without washing. The gelatin sponge impregnated with growth factor-free normal saline was used as control.
Analysis of bone regeneration Micro computed tomography (Micro CT) was performed at 0, 1, 2, 3, and 4 weeks after administration of growth factors using Laboratory MicroCT Scanner (GE Healthcare, London, Canada).
Quantitative analysis of the bone regeneration was performed as previously described 29) . Briefly, the obtained digital images were pixels. The number of pixels of the areas with bone defects (black area) was determined using the magic wand tool (tolerance setting; 20, histogram pixel setting; cache level 1) by a single blinded investigator and confirmed by a second independent investigator.
These data were then used to calculate the bone regeneration rate [(postoperative -preoperative)/ preoperative pixels × 100 %] in each injury site.
Histological observation At 1, 2, 3, and 4 weeks, animals were sacrificed by CO 2 asphyxiation or cervical dislocation. The calvaria were harvested, formalin-fixed, decalcified in 8% EDTA, and paraffin-embedded or frozen section compound-embedded. Hematoxylin and eosin staining was performed on every 10 th section throughout the sample to examine the histological features in a detailed manner.
Immunostaining Immunostaining was performed as previously described 30, 31) .
Briefly, after adding blocking serum [5% normal house serum in phosphate buffer solution (PBS)], specimens were incubated with primary antibodies, Ki67 (1:100, Dako, Denmark) and ostepontin (1:100, R&D, MN), at 4 C overnight. After washing with PBS, specimens were incubated with a secondary antibody, Alexa Fluor 546 (1:500, Invitrogen, Japan) or MAX-PO (Rat) IgG conjugated Fab (Nichirei, Japan). Immunoreactivity was visualized with a DAB (3, 3'-diaminobenzidine) Substrate kit (Vector laboratories, Burlingame, CA, U.S.A) for 1 10 min and then counterstained lightly with hematoxylin. Specimens were observed using a BX51 microscope (Olympus, Tokyo, Japan) or confocal laser-scanning microscope (C1si, Nikon, Japan). Control specimens were incubated directly with secondary antibodies in the absence of primary antibodies and processed as above. No significant positive immunoreactivity was found in controls.
Flk1-GFP mice in vivo imaging
Flk1-GFP mice (8 weeks old, male) that were administered green fluorescent protein (GFP) combined with an Flk1 promoter [32] [33] [34] were used in the same osteogenesis experiment. On the third and seventh days, these mice were sacrificed. Their images were obtained using fluorescent stereo microscopy (MZ16FA, Leica, Germany) and confocal laser scanning microscopy (FV300, Olympus, Japan).
Statistical analysis
The mean ± standard deviation (SD) was calculated for all data. Statistical significance for the two groups was assessed using the Student's t-test. The probability level at which differences were considered significant was P < 0.05.
Results
Stimulatory effect of the combination of HGF and BMP-2 on bone repair
First, to find an effective combination of growth factors for bone regeneration, we implanted gelatin sponges with BMP-2, FGF-2, HGF, and their combinations in the bone defects. After 4 weeks, we assessed bone healing using micro CT. The defects treated with HGF alone (HGF), those treated with a combination of BMP-2 and FGF-2 (BMP-2+FGF-2), and those treated with FGF-2 alone (FGF-2) showed little to no healing, similar to those treated with normal saline (Fig. 1A, B, C and D) . In comparison, the defects treated with BMP2 alone (BMP-2) showed some healing from the defect edges inward, but the majority of the defects showed no osseous healing (Fig. 1E) . Finally, the defects treated with the combination of BMP-2 and HGF (BMP-2+HGF) showed robust bone regeneration and near complete healing as revealed by micro CT (Fig. 1F) . Quantitative analysis demonstrated that the defects treated with normal saline, HGF alone, BMP-2+FGF-2, and FGF-2 alone healed by less than 20% after 4 weeks.
The defects treated with BMP-2 alone showed a moderate increase in healing. Finally, the defects treated with BMP-2+HGF showed approximately 80% healing after 4 weeks of treatment (Fig. 1 G) .
Next, we compared bone healing of the cranial defects treated with BMP-2 alone and those treated with BMP-2+HGF over time. The defects treated with both BMP-2 and BMP-2+HGF showed some increase in bone healing from defect edges inward until 2 weeks. However, while the defects treated with BMP-2 showed small peninsulas of bony regenerate and some healing of defect edges inward after 3 and 4 weeks, those treated with BMP-2+HGF
showed rapid increase of bone healing inside the defect after 3 weeks, and the defect was almost filled with the reorganized mineralized tissues after 4 weeks ( Fig. 2A) . Quantitative analysis (Fig. 2B ).
Histological observation of bone defects
To verify our micro CT findings and investigate the detailed effects of BMP-2+HGF and BMP-2 over time, we observed the histological changes. After 1 week, the area of the remaining gelatin sponge in the defects treated with BMP-2+HGF was smaller than those treated with BMP-2, and a massive cellular filtration into the gelatin sponge was observed in the defects treated with BMP-2+HGF ( Fig. 3A and B region surrounded by a dotted yellow) . Compared with those treated with BMP-2 (Fig. 3C ), more formation of newly woven bone (Fig. 3D arrow heads) and blood vessels (Fig. 3D arrows) were also detected at the bony defect edge in the defects treated with BMP-2+HGF. After 2 weeks, whereas the gelatin sponge still remained in the defects treated with BMP-2 ( Fig. 3E arrow heads) , in those treated with BMP-2+HGF, the gelatin sponge had almost disappeared (Fig. 3F) , and the formation of woven bone at the defect edge and the bottom of the regenerated tissue was much more apparent ( Fig. 3F arrow heads). After 3 weeks, in the defects treated with BMP-2, whereas a little new bone formation was detected only at the defect edge, and the middle of the defect area was filled with fibrotic connective tissue (Fig. 3G) , robust trabecular bone connected each side of the defect and was thickened vertically (Fig. 3H) . In the defects treated with BMP-2+HGF, the bone defect area was completely filled with thick trabecular bone and bone marrow after 4 weeks (Fig. 3J) . In contrast, in the defects treated with BMP-2, most of the defect area was filled with fibrous connective tissue (Fig. 3I) .
Furthermore, we confirmed that the regenerated bone tissue of the defects treated with BMP-2+HGF at 4 weeks was positive for osteopontin by immunostaining (Fig. 3L) .
The effect of HGF on angiogenesis during bone regeneration in vivo
Next, we investigated how HGF promoted bone regeneration in vivo. Osteogenesis is closely related to angiogenesis, and HGF reportedly has strong angiogenic activity [35] [36] [37] . Besides, our data in Fig. 3 showed that BMP-2+HGF induced more blood vessels than BMP-2 alone in the early phase of bone healing (1 week). Hence we hypothesized that HGF potently facilitates bone healing by promoting angiogenesis during the early phase of bone regeneration in vivo. To verify this hypothesis, we performed the calvarial bone defect experiment using FLK1-GFP mice. On day 3, when we directly observed the defect sites, the emergence of a GFP positive area with a cord-like structure toward the bone defect edge was more prominent in the defects treated with BMP-2+HGF compared with those treated with BMP-2 (Fig. 4) . On day 7, quantitative analysis of histological sections showed that the Flk1- GFP positive area was significantly wider in the defect edge area of the defects treated with BMP-2+HGF than in those treated with BMP-2 ( Figure 5A and B) . Moreover, the number of double positive cells for Flk-1 GFP and Ki67, which is a marker for proliferation, was higher both in the defect edge area and in the surface area of the defects treated with BMP-2+HGF than in those treated with BMP-2 ( Fig. 5A and C) . Tomoyuki Masuda et al.: Effect of BMP-2 and HGF on Osteogenesis to identify new approaches to facilitate bone formation, evidenced by numerous completed and ongoing clinical trials as well as basic studies on growth factor administration for induction of osteogenesis. In our study, we sought to determine the optimal condition for the administration of single or combined growth factors in critical-size bone defects in mice, and demonstrated that the combination of BMP-2 and HGF was markedly efficient in bone regeneration due to the promotion of angiogenesis in the early phase of bone repair.
Our micro CT findings showed that the bone defects treated with BMP-2+HGF were filled with calcified tissue until 4 weeks after surgery, whereas the defects treated with other growth factors and their combinations were not. Further, HGF stimulated the proliferation of Flk1-GFP positive cells in the early phase of bone repair. The Flk1 (VEGFR-2) gene encodes a receptor for vascular endothelial growth factor A, C, D, and E 38) and is expressed abundantly in endothelial cells during the early stage of embryonic development 39) . In adults, Flk1 expression is restricted to endothelial cells and transiently up-regulated during angiogenesis 40, 41) . These results suggested that angiogenesis induced by HGF in the initial stage was a vital event to facilitate bone regeneration. HGF, originally identified as a growthpromoting factor for mature hepatocytes 42) , is a multi-functional growth factor that simulates the proliferation and migration of endothelial cells and has angiogenic properties 43, 44) . The HGF receptor c-Met is expressed in endothelial cells and is up-regulated after switching to angiogenic growth conditions 45) . Endothelial cells with increased c-Met expression were more responsive to HGF 45) . HGF implants in mouse subcutaneous tissue and rat corneas have resulted in an in-growth of new blood vessels 46) . It was demonstrated in a rabbit hind limb model of ischemia that HGF stimulated angiogenesis more efficiently than VEGF 47) . The growth and development of vasculature is one of the earliest events in organogenesis, and the factors and events that lead to the normal development of the embryonic vasculature are recapitulated during situations of neoangiogenesis in adults 48) . In an osteodistraction model, angiogenesis predominantly occurred before the onset of osteogenesis during bone lengthening 49) . Previous reports demonstrated that angiogenesis played a pivotal role in bone repair, that an effectual vascular supply was essential for bone regeneration to successfully occur [21] [22] [23] 50) , and that during the process, the early vascular response is highly sensitive to initial micromovement 51) . Conversely, inhibiting angiogenesis prevents bone fracture healing 52) . Together with these facts and our findings, it is suggested that in our experimental model, newly formed vasculature facilitated by HGF could first provide the necessary factors such as growth factors, hormones, chemokines, metabolites, and numerous cell types which contribute to osteogenesis, consequently promoting bone formation.
In addition to the angiogenic capacity, in the early phase of our bone defect model, absorption of the gelatin sponge was more accelerated in the defects treated with BMP-2+HGF compared with those treated with BMP-2. In the defects treated with BMP-2+HGF, most of the gelatin sponge was absorbed and replaced by newly formed bone with bone marrow four weeks after surgery. Since HGF is a potent antifibrotic agent 53) and facilitates the resorption of the biological scaffold 54) comprising extracellular matrix, HGF may help to promote the absorption of the gelatin sponge, which could improve the environment for bone regeneration in the defect area. However, the impact of HGF on the degradation of extracellular matrix is still under investigation.
Besides targeting endothelial cells, the influence of HGF on osteoblast differentiation is reported in several papers, although different mechanisms and even opposing effects have been described. HGF and its receptor, c-Met, are also expressed in both osteoblasts and osteoclasts 55, 56) . HGF, in combination with vitamin D3, facilitates growth and differentiation of human mesenchymal stem cells into osteogenic cells 57) . At the fracture site, HGF induces the up-regulation of BMP receptors in mesenchymal cells during the early phase of fracture repair 17) . Furthermore, HGF was reported to stimulate osteoblast differentiation based on angiogenic properties in combination with hydroxyapatite 58, 59) . Since endothelial cells can produce BMP-2 60) and osteoblasts secreted HGF 61) during bone repair, in our experimental model, endothelial cells activated by exogenous HGF may produce BMP-2 that can act on osteoblasts as an osteogenic signal, and in turn, the activated osteoblasts may secrete HGF to further promote angiogenesis. In contrast, inhibitory effects of HGF on osteoblast differentiation have also been proposed. HGF inhibited BMP-induced osteoblastogenesis from human mesenchymal stem cells in vitro 19) . HGF also displayed significantly reduced ectopic bone formation in muscle induced by BMP-2, while treatment with HGF prior to the administration of BMP-2 did not influence subsequent osteoblast differentiation induced by BMP-2 18) . These discrepancies may arise from the differences in experimental conditions such as cells and animals, the dose of growth factors, and variations in surgical procedures. Hence, the mechanism whereby HGF regulates osteoblast differentiation should be assessed further.
Our data indicate the potential application of the combination of HGF and BMP-2 for treating bone defects, and the importance of the induction of angiogenesis in the early phase of bone healing. Use of this method could shorten the duration of treatment for bone defect, which would achieve physical and mental well-being of patients and reduce their economic burden. However, before clinical application, challenges to be addressed still remain. Because the critical sequential timing and the optimal dose of the secreted factors such as HGF and BMP-2 tightly regulate the reparative/regenerative mechanism during bone repair, the appropriate timing and dosing should be elucidated, and a suitable scaffold which releases the factors in a spatiotemporally regulated manner to promote osteogenesis should be developed. Safety concerns should also be evaluated, for example, whether or not to generate tumors and induce an intense inflammation response. To clarify the precise mechanism of bone regeneration, further studies are necessary to determine the molecular mechanism by which other factors regulate angiogenesis in the early phase of bone healing.
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